Victory Capital Management Inc. Has $1.02 Million Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)

Victory Capital Management Inc. reduced its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 39.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 21,716 shares of the biopharmaceutical company’s stock after selling 13,888 shares during the period. Victory Capital Management Inc.’s holdings in Cytokinetics were worth $1,022,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of CYTK. Charles Schwab Investment Management Inc. raised its holdings in Cytokinetics by 42.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,321,391 shares of the biopharmaceutical company’s stock worth $69,769,000 after buying an additional 395,709 shares during the period. Westfield Capital Management Co. LP raised its holdings in Cytokinetics by 38.9% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,212,886 shares of the biopharmaceutical company’s stock worth $64,040,000 after buying an additional 339,373 shares during the period. Checkpoint Capital L.P. raised its holdings in Cytokinetics by 145.7% during the 3rd quarter. Checkpoint Capital L.P. now owns 466,813 shares of the biopharmaceutical company’s stock worth $24,648,000 after buying an additional 276,813 shares during the period. Two Sigma Advisers LP acquired a new stake in Cytokinetics during the 3rd quarter worth approximately $11,336,000. Finally, Janus Henderson Group PLC raised its holdings in Cytokinetics by 17.2% during the 3rd quarter. Janus Henderson Group PLC now owns 1,143,830 shares of the biopharmaceutical company’s stock worth $60,399,000 after buying an additional 167,501 shares during the period.

Insiders Place Their Bets

In other Cytokinetics news, EVP Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $45.92, for a total transaction of $91,840.00. Following the completion of the transaction, the executive vice president now directly owns 116,071 shares of the company’s stock, valued at $5,329,980.32. The trade was a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Andrew Callos sold 2,775 shares of Cytokinetics stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.38, for a total transaction of $123,154.50. Following the transaction, the executive vice president now directly owns 34,888 shares of the company’s stock, valued at approximately $1,548,329.44. This trade represents a 7.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 43,834 shares of company stock valued at $1,949,275 over the last ninety days. 3.40% of the stock is currently owned by company insiders.

Cytokinetics Trading Down 0.8 %

CYTK stock opened at $43.10 on Friday. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. The company has a fifty day moving average price of $45.99 and a two-hundred day moving average price of $50.04. Cytokinetics, Incorporated has a one year low of $40.53 and a one year high of $75.71. The stock has a market cap of $5.10 billion, a price-to-earnings ratio of -8.01 and a beta of 0.95.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) EPS for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.03. The company had revenue of $16.93 million for the quarter, compared to the consensus estimate of $14.26 million. Equities analysts anticipate that Cytokinetics, Incorporated will post -5.24 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CYTK. JMP Securities reaffirmed a “market outperform” rating and set a $78.00 price target on shares of Cytokinetics in a research note on Friday, February 7th. Stifel Nicolaus began coverage on shares of Cytokinetics in a research note on Wednesday, January 22nd. They set a “buy” rating and a $80.00 price target for the company. Mizuho raised their price target on shares of Cytokinetics from $99.00 to $103.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Morgan Stanley set a $67.00 price target on shares of Cytokinetics in a research note on Friday, March 7th. Finally, Evercore ISI raised shares of Cytokinetics to a “strong-buy” rating in a research note on Friday, February 7th. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.00.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.